Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Smith & Nephew Snats ADR (NY: SNN )

23.91 -0.10 (-0.40%)
Streaming Delayed Price Updated: 11:29 AM EDT, Apr 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Smith & Nephew Snats ADR

< Previous 1 2 Next >
Smith+Nephew announces new evidence supporting ALLEVYN LIFE Foam Dressing’s role in pressure injury prevention
From Smith & Nephew UK Ltd
Via GlobeNewswire
Smith+Nephew’s PICO™ Single Use Negative Pressure Wound Therapy System provides better clinical outcomes versus standard of care according to UK National Institute for Health and Care Excellence (NICE)
From Smith & Nephew UK Ltd
Via GlobeNewswire
Smith+Nephew introduces the RENASYS™ EDGE Negative Pressure Wound Therapy System – an exciting new option in home-based care for patients living with chronic wounds
From Smith & Nephew UK Ltd
Via GlobeNewswire
Earnings Scheduled For August 3, 2023
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million. 
Via Benzinga
Will Investors Notice Exciting Sign On Smith & Nephew's Chart?
Via Benzinga
Smith & Nephew's Implant Shows 86% Reduction In Re-Tear Rates After Shoulder Surgery
Via Benzinga
Smith+Nephew teams up with UFC to be first-ever Preferred Sports Medicine Technology Partner
From Smith & Nephew UK Ltd
Via GlobeNewswire
7 Robotic Surgery Stocks to Buy for the Future of Healthcare
Discover seven robotic surgery stocks primed for growth as the industry evolves. Unveil opportunities in a market set to double by 2033. 
Via InvestorPlace
British MedTech Firm Smith & Nephew Seeks To Adopt US-Inspired Pay Policy to Navigate Shareholder Skepticism
Smith & Nephew shakes up executive pay structure, aligning with US standards to curb turnover. Chairman Rupert Soames addresses global talent recruitment challenges and the shift's significance in the... 
Via Benzinga
Smith+Nephew and U.S. Army Institute of Surgical Research to engage in Master Cooperative Research and Development Agreement
From Smith & Nephew UK Ltd
Via GlobeNewswire
Smith & Nephew Shares Fall On Lower Margins As Cost Headwinds Hit Q2 Profit
Via Benzinga
3 Millionaire-Maker Robotics Stocks to Buy in February 2024
Jump into the future with top robotics stocks poised for explosive growth. Discover the potential for massive returns. 
Via InvestorPlace
Smith+Nephew announces commercial launch of its AETOS™ Shoulder System for anatomic and reverse shoulder replacement at AAOS 2024 Annual Meeting
From Smith & Nephew UK Ltd
Via GlobeNewswire
Smith+Nephew to showcase leading, innovative AI-driven robotic-assisted solutions for personalized orthopaedic surgery at AAOS 2024 Annual Meeting
From Smith & Nephew UK Ltd
Via GlobeNewswire
Smith+Nephew unveils expanded Sports Medicine portfolio to enable biological healing at AAOS 2024 Annual Meeting
From Smith & Nephew UK Ltd
Via GlobeNewswire
New study confirms Smith+Nephew’s REGENETEN™ Bioinductive Implant reduces full-thickness rotator cuff re-tear rates¹ by 68%
From Smith & Nephew UK Ltd
Via GlobeNewswire
Santa Rally comes early for these stocks
The analysts are upgrading these stocks and are helping an early Santa Claus Rally drive their prices to new highs, with a double-digit upside ahead. 
Via MarketBeat
Alphabet To Rally Over 10%? Here Are 10 Other Analyst Forecasts For Wednesday
Citigroup raised the price target for LyondellBasell Industries N.V. (NYSE: LYB) from $104 to $106. Citigroup analyst Patrick Cunningham upgraded the stock from Neutral to Buy. LyondellBasell... 
Via Benzinga
Smith & Nephew Raises Revenue Growth Outlook After Strong 1H Performance, Sports Medicine and Wound Management Show Strength
Smith & Nephew PLC (NYSE: SNN) reported improved revenue, profit, and margin in the  
Via Benzinga
AstraZeneca, ECARX Holdings And Other Big Stocks Moving Lower On Monday
U.S. stocks traded mixed, with the Dow Jones dropping around 30 points on Monday. Here are some big stocks recording losses in today’s session. Protagonist Therapeutics, Inc. (NASDAQ: PTGX) shares... 
Via Benzinga
Amgen Out, Rio Tinto In As Morgan Stanley Shuffles Dividend Deck
Via Benzinga
Boeing, CyberArk Lead 5 Stocks Near Buy Points
The market rally is going strong, but watch out for a potential pullback. 
Via Investor's Business Daily
Surgical Centers, Med-Tech Stocks Up On Pent-Up Surgical Demand
Surgery centers and medtech firms see a surge in demand as joint replacements and other elective surgeries are rescheduled, causing challenges for insurers. 
Via MarketBeat
UnitedHealth's Bad News Hits Insurers, But Surgery Partners Signals Breakout
UNH stock slumped after UnitedHealth said more seniors are getting hip and surgery procedures. That sent Surgery Partners stock soaring. 
Via Investor's Business Daily
Top 5 Health Care Stocks That Could Sink Your Portfolio This Quarter
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
3 Healthcare Dividend Payers With Big Price Growth
Sanofi, AstraZeneca and Smith & Nephew all boast price performance better than about 80% of the broader market, and all are dividend payers. 
Via MarketBeat
Burberry Finance Chief Joins GSK As First Woman CFO
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  Tuesday's session saw 63 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday, 92 companies set new 52-week lows. 
Via Benzinga
This Healthcare Stock Tumbled 43%; Here Are 88 Biggest Movers From Yesterday
Gainers Athersys, Inc. (NASDAQ: ATHX) climbed 71.1% to close at $0.3250 on Thursday after gaining 10% on Wednesday. Athersys is expected to release its Q2 financial results on Thursday, August 11,... 
Via Benzinga
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.